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Background: In the HD14 trial, 2× BEACOPPescalated + 2× ABVD (2 + 2) has improved the primary outcome.
Compared with 4× ABVD, this beneﬁt might be compromised by more infertility in women. Therefore, we analyzed
gonadal function and fertility.
Patients and methods: Women ≤45 years in ongoing remission at least 1 year after therapy were included.
Hormone parameters, menopausal symptoms, measures to preserve fertility, menstrual cycle, pregnancies, and
offspring were evaluated.
Results: Three hundred and thirty one of 579 women addressed participated (57.2%) and 263 per-protocol treated
patients qualiﬁed (A = ABVD: 137, B = 2 + 2: 126, mean time after therapy 42 and 43 months, respectively). Regular
menstrual cycle after treatment (A: 87%, B: 83%) and time to recovery (≤12 months) were not different. Follicle-
stimulating hormone and anti-Muellerian hormone were signiﬁcantly better in arm A. However, pregnancies after therapy
favored arm B (A: 15%, B: 26%, P = 0.043) and motherhood rates were equivalent to the German normal population.
Multivariate analysis revealed prophylactic use of gonadotropin-releasing hormone (GnRH) analogues as highly
signiﬁcant prognostic factor for preservation of fertility (odds ratio = 12.87, P = 0.001). Severe menopausal symptoms
were frequent in women ≥30 years (A: 21%, B: 25%).
Conclusions: Hormonal levels after 2 + 2 indicate a reduced ovarian reserve. However, 2 + 2 in combination with
GnRH analogues does not compromise fertility within the evaluated observation time.
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introduction
Hodgkin lymphoma (HL) has become a curable malignancy
over past decades. The disease is usually treated with a
combination of chemotherapy and involved-ﬁeld radiotherapy
(IFRT). With progression-free survival rates ∼87% in early
unfavorable stages, there are many long-term survivors, most
of them of young age [1, 2]. Thus, there is a need to analyze
long-term side-effects and to carefully consider the risk to
beneﬁt ratio of established as well as of newly introduced
treatment regimens. Among these treatment-related toxic
effects, gonadal dysfunction and infertility are especially
relevant because they affect the quality of many life-years [3].
The problem of gonadal dysfunction is more pronounced in
women than in men for two reasons. First, chemotherapy can
result in gonadal dysfunction and impaired spermatogenesis
(exocrine hypogonadism) but usually does not lead to clinically
signiﬁcant endocrine hypogonadism with normal testosterone
levels in most men [4]. In contrast, female gonadal dysfunction
after chemotherapy often includes endocrine hypogonadism
and premature ovarian failure [5]. Both are compromising
quality of life and can cause medical problems such as
osteoporosis and long-term cardiovascular disease [6].
Secondly, preservation of fertility is much easier and more
established in men than in women: semen analysis and
cryopreservation of sperm are a standard procedure before
chemotherapy. For established fertility preservation techniques
in women, time and a partner are needed and the
cryopreservation of oocytes or ovarian tissue is more invasive
and still does not yield satisfactory results [7].
It has been shown for both male and female patients that the
rate of treatment-induced infertility increases with more
aggressive chemotherapy [4, 8, 9]. Alkylating agents, especially
procarbazine and cyclophosphamide, have a strong negative
impact on fertility. These drugs are included in the BEACOPP
regimen (bleomycin, etoposide, adriamycin,
cyclophosphamide, vincristine, procarbazin, prednisone) that
had mainly been used in advanced-stage HL. In contrast,
ABVD (adriamycin, bleomycin, vinblastine, dacarbazine), the
standard of care for early-stage HL, is regarded less
gonadotoxic [10–12].
In the German Hodgkin Study Group (GHSG) HD14 study,
escalation of chemotherapy using 2× BEACOPPescalated + 2×
ABVD (arm B, 2+2) compared with 4× ABVD (arm A)
provides a better outcome with an estimated 4-year freedom
from treatment failure rate of 94.7% compared with 89.3% [13].
However, this improved tumor control must be carefully
balanced against the presumed negative long-term toxicity
such as infertility or gonadal dysfunction. The main objective
of the present analysis was therefore to assess gonadal function
and fertility in female survivors treated with the new 2 + 2
regimen as compared with four cycles of ABVD.
patients and methods
HD 14 trial: patients and study design
Patients between the age of 18 and 60 with biopsy-proven HL of clinical
stages IA, IB, IIA or IIB with at least one of the following risk factors were
included: bulky mediastinal mass (≥1/3 maximum transverse thorax
diameter), extranodal involvement, erythrocyte sedimentation rate ≥50
mm/h (or ≥30 mm/h in patients with ‘B’ symptoms), or three or more
lymph node areas involved. Patients with stage IIB disease and bulky
mediastinal mass and/or extranodal involvement were not included.
Patients with impaired heart, lung, liver, or kidney function; previous
malignant disease, or HIV-positive status were excluded. Patients were also
excluded if they were pregnant or lactating. The study was carried out in
accordance with the Declaration of Helsinki and the International
Conference on Harmonization guidelines for Good Clinical Practice (ICH-
GCP). Randomization was carried out at the GSHG central trial ofﬁce into
treatment arms A (four cycles of ABVD) or B (two cycles of
BEACOPPescalated plus two cycles of ABVD). Chemotherapy was followed
by standard 30 Gy IFRT.
assessment of gonadal function and fertility
Gonadal function and fertility after treatment were evaluated by contacting
all female patients (18–40 years at time of randomization) in ongoing
remission at least 1 year after therapy and without any other chemotherapy
treatment than the HD14 study medication (i.e. exclusion of relapsed
patients). Patients had to have signed written informed consent that
allowed us to address them for questions related to their initial treatment.
questionnaires
Menopausal symptoms were determined using the Menopause Rating Scale
(MRS) [14, 15]. Additional questions referred to the use of hormonal
substitution, methods of fertility preservation before therapy, menstrual
status, pregnancies and offspring, hormonal analyses, and social aspects.
Additionally applied, but not reported here, were quality-of-life
assessments using the QLQ-C30 questionnaire [16].
hormonal analysis
Patients were asked to take a blood sample at the end of the pill break or at
day 3 of a new menstrual cycle and to send them to us for analysis of
hormones. Blood samples were then processed and stored at −20°C until
analysis. Endocrine screening included standardized serum assays for
follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol
[heterogenic, noncompetitive chemiluminescent immunometric assays,
Elecsys-LH, Elecsys-FSH, Elecsys-Estradiol-II (Roche Diagnostics GmbH,
Mannheim, Germany)], and anti-Muellerian hormone (AMH) [active
AMH Gen II ELISA (Beckman Coulter Company, Praha, Czech Republic)].
statistics
To allow conclusive analysis of treatment consequences, we analyzed only
per-protocol treated patients of the HD14 study. The main analysis set
included females ≤40 years at ﬁrst diagnosis of HL and ≤45 years at time
of fertility assessment who were survivors in ongoing remission at least 1
year after therapy. A further analysis set was used for multivariate
prediction of pregnancies. For this analysis set, only women taking no
hormonal contraceptives at time of assessment and having a male partner
for sexual intercourse were included (core set). As age is a crucial factor for
fertility, most results are separately reported for survivors in age groups of
18–29 years and 30–45 years.
Outcome measures of fertility were pregnancies after therapy (primary
outcome measure), other direct indicators (regular cycle, time to regular
cycle), hormonal parameters (FSH, AMH, LH, estradiol), and menopausal
symptoms (MRS). Hormonal parameters were natural log transformed
before statistical computations to normalize distributions.
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To evaluate effects of age, motherhood before therapy, time since end of
chemotherapy, use of gonadotropin-releasing hormone (GnRH) analogues,
oral contraception, and treatment on pregnancies, a logistic regression in
the core set was computed. Recent data on motherhood in Germany were
used to compare motherhood rates of our treatment groups with
representative reference data in ﬁve age groups.
Figure 1. Consort chart. CT, chemotherapy; PFS, progression-free survival.
Table 1. Patient characteristics
Per protocol Total set
Participating Not participating Participating Not participating
4× ABVD 2 + 2 4× ABVD 2 + 2
N 137 126 142 154 331 230
Age at fertility assessment y 32 ± 7 (20–45) 32 ± 7 (20–44) n.a. n.a. 32 ± 7 (20–45) n.a.
Age at HL diagnosis y 28 ± 7 (18–39) 28 ± 7 (18–39) 27 ± 7 (18–39) 28 ± 6 (18–39) 28 ± 7 (18–39) 27 ± 7 (18–39)
Treatment duration w 15 ± 1 (11–21) 13 ± 1 (11–17) 15 ± 2 (2–21) 13 ± 2 (5–23) 14 ± 3 (2–23) 14 ± 2 (2–23)
Time from end of CT m 42 ± 20 (12–83) 43 ± 19 (12–77) n.a. n.a. 39 ± 22 (12–83) n.a.
Ann Arbor Stage 1A 3 (2%) 1 (1%) 2 (1%) 3 (2%) 5 (2%) 4 (2%)
1B 3 (2%) 2 (2%) 1 (1%) 4 (3%) 6 (2%) 4 (2%)
2A 105 (77%) 101 (80%) 104 (74%) 101 (80%) 236 (78%) 175 (76%)
2B 26 (19%) 22 (18%) 33 (24%) 19 (15%) 54 (18%) 46 (20%)
B symptoms yes 31 (23%) 25 (20%) 32 (23%) 26 (21%) 64 (21%) 50 (22%)
Large mediastinal mass yes 30 (22%) 32 (25%) 35 (25%) 34 (27%) 73 (24%) 58 (25%)
Extranodal involvement yes 13 (10%) 10 (8%) 9 (6%) 13 (10%) 32 (11%) 13 (6%)
≥3 nodes yes 98 (72%) 87 (69%) 92 (66%) 95 (75%) 210 (70%) 162 (71%)
High ESR yes 69 (50%) 67 (53%) 74 (53%) 70 (56%) 158 (53%) 122 (53%)
IPS 0–1 112 (87%) 102 (86%) 108 (82%) 100 (85%) 247 (87%) 175 (83%)
2–3 17 (13%) 16 (14%) 23 (18%) 18 (15%) 37 (13%) 37 (18%)
Motherhood before yes 54 (41%) 41 (35%) 41 (35%) 44 (33%) 114 (37%) 66 (34%)
Pill yes 45 (34%) 41 (33%) n.a. n.a. 103 (32%) n.a.
GnRH yes 25 (19%) 36 (29%) n.a. n.a. 78 (24%) n.a.
Contraception now yes 64 (49%) 65 (52%) n.a. n.a. 158 (49%) n.a.
Sex partner now yes 117 (89%) 113 (90%) n.a. n.a. 287 (89%) n.a.
Continuous data: mean ± standard deviations (range), categorical data: frequencies (percent of valid answers).
CT, chemotherapy; ESR, erythrocyte sedimentation rate; GnRH, gonadotropin-releasing hormone; HL, Hodgkin lymphoma; m, months; n.a., not available
because information requires participation; w, weeks; y, years.
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The level of signiﬁcance was set to 0.05 two-sided. Continuous
parameters were tested with t-test for independent groups, categorical data
with binomial test, and no corrections for multiple testing were applied. All
statistical analyses were computed with Statistical Analysis System release
9.2. (SAS Institute, Cary, NC).
results
patient characteristics
A total of 331 (57.2%) of 579 contacted women participated
(arm A: 157, arm B: 174). After excluding patients being less
than ﬁrst 12 months after therapy or those with additional
therapy or protocol deviations, the per-protocol analysis set
included 263 women (arm A: 137, arm B: 126). For the
multivariate analysis of predictors of fertility, only women
without contraception and reporting sexual intercourse were
included, resulting in a core set of 117 patients (arm A: 62,
arm B: 55; Figure 1).
Comparison of the per-protocol analysis set and the entire
HD14 cohort showed no relevant differences in terms of
patient, treatment, or lymphoma characteristics (Table 1).
Mean age at fertility assessment was 32 years in both arms and
mean observation time from end of treatment was 42 months
in arm A and 43 months in arm B. All patient characteristics
were well balanced between the two treatment groups except
for the use of GnRH analogues during chemotherapy which
were given more frequently in the 2 + 2 group (29%) compared
with those treated with 4× ABVD (19% Table 1).
hormonal analysis
Serum levels of AMH and FSH were different between the
treatment arms. These differences in favor of ABVD were high
and signiﬁcant for FSH in older women (30–45 years at
assessment: arm A: 4.4 U/l, arm B: 11.9 U/l) and for AMH in
both age groups (18–29 years at assessment: arm A: 2.2 μg/l,
arm B: 0.9 μg/l; 30–45 years at assessment: arm A: 0.8 μg/l,
arm B: 0.03 μg/l) (Table 2).
menopausal symptoms
There was no signiﬁcant difference between treatment arms in
menopausal symptoms as measured by MRS total score. The
same is true for any of the subdimensions of the MRS
(urogenital, psychological and somato-vegetative; data not
shown). However, both arms showed an age-related increase of
menopausal symptoms and more severe symptoms than in a
45- to 60-year-old German reference cohort (Table 2) [14].
menstrual status
Over 90% of the patients ≤30 years reported a regular cycle
with no difference between treatment arms. In the older group,
84% in arm A had a regular cycle compared with 74% in arm
B. This difference was not signiﬁcant (Table 2).
The time to regular menstrual cycle after therapy was
almost equal between treatment arms. With very rare
exceptions, recovery of regular menstrual cycle was
completed within 12 months. The use of GnRH analogues
during therapy deferred recovery of a regular cycle for ∼1
month (Figure 2a and b).
Table 2. Fertility parameters of per-protocol treated survivors in two age groups and for the two treatment arms (A: 4× ABVD, B: 2× BEACOPPescalated +
2× ABVD)
18–29 years 30–45 years
N valid Aa Ba A–Ba N valid Aa Ba A–Ba
A, B 48 58 106 A, B 89 68 157
Hormonesb
AMH [μg/l]b 48, 58 2.2 0.9 +1.3 *** 88, 68 0.8 0.03 +0.8 ***
FSH [U/l]b 46, 55 3.0 4.3 −1.3 88, 67 4.4 11.9 −7.5 ***
Menopausal symptoms (MRS, total score)
MRS total score 38, 45 7.3 6.5 +0.8 67, 52 9.1 9.6 −0.5
MRS severityc 38, 45 67, 52
Severe (8%)c 16% 7% +9% 21% 25% −4%
Moderate (20%)c 16% 22% −6% 19% 17% +2%
Mild (25%)c 32% 22% +10% 30% 29% +1%
No/few (48%)c 37% 49% −12% 30% 29% +1%
Patient reported events after HL therapy
Regular Cycle after therapy 46, 55 100% 100% 0% 83, 68 94% 90% +4%
Regular Cycle presently 46, 57 91% 95% −3% 83, 68 84% 74% +11%
Pregnancy 47, 55 13% 22% −9% 83, 67 17% 30% −13%
Birth 41, 45 12% 13% −1% 77, 58 12% 28% −16%*
Bold values are statistically signiﬁcant.
Arithmetic means and t-tests for continuous variables, relative frequencies in percent and binomial tests for categorical data.
All computations for AMH and FSH with log-transformed values to normalize distributions; table entries in original units (after exponentiation).
Classiﬁcation of MRS total score with reference scores for 45- to 60-year-old German females in parentheses.
***P ≤ 0.001, *P ≤ 0.05.
AMH, anti-Muellerian hormone; FSH, follicle-stimulating hormone; MRS, Menopause Rating Scale.
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pregnancies and motherhood
In summary, 20 patients in arm A (15%) reported a pregnancy
compared with 32 patients (26%) in arm B (supplemental
Figure S1, available at Annals of Oncology online). The
difference was signiﬁcant (P = 0.043) favoring the more
aggressive arm B (2 + 2). Logistic regression analysis of
potential contributing factors in the core set (Table 3) showed
that motherhood before therapy, age, treatment arm, and oral
hormonal contraception during therapy did not signiﬁcantly
predict pregnancies (all P > 0.10). However, the use of GnRH
Figure 2. Percent of survivors with regular cycle and time to regular cycle for (A) chemotherapy regimen and (B) GnRH.
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analogues during chemotherapy [odds ratio (OR) = 12.87, P =
0.0010] and the time after chemotherapy (P = 0.0008)
signiﬁcantly increased the probability to become pregnant. The
motherhood rates of the main analysis set in ﬁve different age
groups were comparable to representative data of the German
general population (Figure 3) [17].
inﬂuence of GnRH analogues and pregnancies on
hormones
AMH was not sensitive to application of GnRH analogues during
therapy or pregnancies after therapy (core set, P = 0.46 and
p=0.95). Conversely, FSH differed signiﬁcantly between the two
groups with and without pregnancy (P < 0.0001) and differed to
some degree between the two GnRH groups (P = 0.14).
discussion
This study investigated gonadal function and fertility of 263
female HL patients treated within the GHSG trial HD14 for
early unfavorable disease. The following major ﬁndings emerge
from this analysis: First, female fertility, deﬁned as pregnancies
after therapy, is not compromised after two cycles of
BEACOPPescalated in the 2 + 2 regimen as compared with
ABVD only. In addition, motherhood rates in ﬁve different age
groups of our study are equivalent to the respective
motherhood rates of the general German female population
indicating no impairment of fertility at all. Accordingly, a
regular menstrual cycle was reported by most women in both
arms (arm A: 87%, arm B: 83%) and recovery occurred within
1 year after therapy. Secondly, the prophylactic use of GnRH
analogues during therapy was followed by signiﬁcantly more
pregnancies after therapy. Thirdly, serum levels of AMH did
not correlate with the use of GnRH analogues. Fourthly,
hormonal levels of AMH and FSH demonstrate a distinct
difference between both treatment arms in favor of ABVD.
Fifthly, compared with 4× ABVD women do not report more
menopausal symptoms after the BEACOPPescalated containing
regimen (2 + 2). In both arms relevantly more females suffer
from severe menopausal symptoms than expected for a
considerably older reference cohort.
This is the largest study in a uniformly treated and well-
deﬁned patient population on gonadal function and fertility
after chemotherapy. Nonetheless, with regard to female
gonadal function determined by hormonal serum levels, our
results need to be interpreted with caution. The analysis was
carried out after the reported pregnancies and serum samples
were collected locally under non-standardized conditions and
might not be reliable [18]. In addition, a transvaginal
ultrasound to determine the antral follicle count was not
carried out in our patients [19]. However, we included also
AMH in our analysis, i.e. known to be independent of the
menstrual cycle, and is widely discussed as a valuable predictor
of ovarian reserve and reproductive function [19–23].
Though we observed signiﬁcant differences in serum AMH
levels especially in younger women treated with ABVD, there
were more pregnancies in the 2 + 2 arm. Thus, AMH levels
were not conclusive on female fertility in our data. However, as
decreased AMH levels indicate a reduced follicle pool, we
cannot exclude a higher rate of future POF [24]. A longer
follow-up period is needed to proof this potential effect. Since
POF should be accompanied by menopausal symptoms, we
also investigated this issue in our cohort and compared the
results to a representative sample of German women aged
between 45 and 60 years [14]. This is the best matching control
cohort for our analysis as MRS reference scores for younger
women are not available. However, already above the age of 30
years, the rate of females suffering from severe menopausal
symptoms in our study is approximately threefold higher than
in the control cohort. This is true for both regimens and
emphasizes the urgent need for a comprehensive aftercare of
young women after HL.
Finally, amenorrhea has been widely used as an indirect
indicator of gonadal dysfunction after cancer treatment though
regular menstrual period does not necessarily represent an
ovulation [5, 9]. In our study cohort, most women reported a
regular cycle after therapy, again without signiﬁcant differences
between the treatment arms. Interestingly, almost no woman
reported recovery of the menstrual cycle beyond 1 year after
therapy. Thus, our data suggest referring women without a
regular cycle later than 1 year after therapy and desire for
children to a center for reproductive medicine.
Table 3. Logistic regression for prediction of pregnancies after end of CT














Bold values are statistically signiﬁcant.
Continuous variable: OR depends on unit of measurement risk relation for
every increase of 1 month or year.
CT, chemotherapy; GnRH, gonadotropin-releasing hormone; OR, odds
ratio.
Figure 3. Percentage of childless women in ﬁve age groups compared with
representative statistics of the German general population.
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Obviously, apart from any hormonal serum levels, infertility
is the most relevant end point for female HL patients.
Infertility is hard to assess as primary end point in clinical
studies as the inability to conceive or give birth to a child is a
time-dependent parameter. It is, therefore, difﬁcult to diagnose
and evaluate at a given time point. Nevertheless, the most valid
end points for fertility remain the number of pregnancies and
offspring. Unfortunately, only some authors have reported the
number of childbirths after HL therapy, often in small
noncontrolled series [5, 25, 26].
In our study, we observed normal motherhood rates for
patients treated with ABVD and the 2 + 2 regimen that
included the more aggressive BEACOPPescalated chemotherapy.
Even after adjusting for the use of GnRH analogues in the
logistic regression analysis, there was no evidence for impaired
fertility after the 2 + 2 regimen within the evaluated
observation time. This result is even more impressive taking
into account that relapsed HL patients were excluded from
analysis. Relapses occurred more often after ABVD and were
usually treated with high-dose chemotherapy causing infertility
in almost all cases. Thus, in this respect, the current analysis
has a small bias in favor of 4× ABVD.
Despite some methodological limitations of our study, the
investigated cohort is large and the majority of HD14 patients
participated in the survey. In addition, all patients were
uniformly treated with two well-deﬁned regimens. With the
notable exception of GnRH application during treatment,
patient characteristics were well balanced between arms and
were representative for all female survivors.
The prophylactic use of GnRH analogues for ovary
protection during cancer treatment is subject of controversial
discussions. It has been investigated in few prospective
randomized studies with contradictory results. Three of these
trials using surrogate parameters showed no protective effect of
GnRH analogues and two were positive [27–31].
A retrospective study with a more comprehensive approach
including transvaginal ultrasound, found no beneﬁt for GnRH
analogues in terms of ovarian function [32]. However, the
multivariate analysis in the present study reveals that the use of
GnRH analogues during therapy is a strong, independent, and
a highly signiﬁcant predictor of pregnancies. Of course, only
prospective randomized studies could deﬁnitely conﬁrm a
causal relationship between use of GnRH analogues and
preservation of fertility in the unfavorable early stages of HL.
An important confounder in this retrospective analysis might
be the patient’s strong wish to preserve fertility resulting in a
more frequent use of GnRH analogues as compared with
women not expressing this desire. To minimize this effect, we
excluded those women from the multivariate analysis who had
no sexual partner or who used any contraception after therapy
(core set). In addition, we included possible confounders into
the analysis as motherhood before therapy and oral
contraception during therapy. We thereby adjusted our analysis
to a high degree and nevertheless found surprisingly strong
(OR > 12) indirect evidence supporting the prophylactic use of
GnRH analogues in women receiving therapy for early
unfavorable HL.
In summary, 2× BEACOPPescalated followed by 2× ABVD has
a stronger impact on ovarian reserve, reﬂected by reduced
AMH and increased FSH serum levels. However, we cannot
ﬁnd any notable differences between the treatment arms in
terms of the clinically valid end points amenorrhea,
menopausal symptoms, pregnancies, or offspring. Thus,
treatment of early unfavorable HL in young women with the
effective combination of 2× BEACOPPescalated followed by 2×
ABVD and IF-RT has only a subclinical impact on ovarian
function but—within the evaluated observation time—not on
fertility itself, especially when combined with the prophylactic
use of GnRH analogues. This result must be taken into account
when judging the overall beneﬁt of the 2 + 2 regimen for
female early unfavorable HL patients.
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Adding docetaxel to cisplatin and ﬂuorouracil in
patients with unresectable head and neck cancer: a
cost–utility analysis
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Background: Adding docetaxel (Taxotere, T) to induction chemotherapy with platinum/infusional 5-FU (PF) has been
shown to improve overall survival of patients with head and neck cancer. The aim of the study was to analyze the cost–
utility of TPF in patients with unresectable disease.
Design: We developed a Markov model to represent patient’s weekly transitions among different health states, related
to treatment or disease status. Transition probabilities were obtained from the TAX 324 clinical trial report and from the
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